Compounded semaglutide alternatives: 9 options, FDA status spelled out
The closest compounded semaglutide alternatives with FDA approval are Wegovy, as a daily pill or weekly pen, and Ozempic for type 2 diabetes. Zepbound and Foundayo are approved options with different molecules. Compounded tirzepatide and compounded semaglutide tablets cost less but, like the injection, are not FDA-approved.
The medication in brief
Compounded semaglutide is semaglutide prepared by a pharmacy rather than made by Novo Nordisk, usually as a multi-dose vial and often with an added ingredient such as glycine or B12. It is not FDA-approved and not a generic of Wegovy or Ozempic; the FDA does not review it for safety, effectiveness or quality before sale (FDA, updated 1 Oct 2026). At Temi in California it starts at $59.99 for a 7.5 mg vial, plus a $39 prescription service (Temi compounded semaglutide page, checked 5 Oct 2026). People look for alternatives because the shortage that allowed broad compounding ended in February 2025, providers have changed what they offer, and approved brands now sell for cash at lower prices than before.
Why people look for alternatives
The shortage that drove compounding is over
FDA declared the semaglutide injection shortage resolved on 21 February 2025, and its grace period for 503A pharmacies making copies ended in April 2025 (FDA compounding policy page). Some providers stopped offering it as a result.
Brand cash prices came down
The Wegovy pill starts at $149 a month and the pen at $199 for two introductory fills, then $349 (NovoCare Wegovy price page, checked 5 Oct 2026). The gap to compounded pricing is narrower than it was.
Wanting an approved product
The FDA has logged 990 adverse event reports tied to compounded semaglutide as of 31 May 2026, including dosing errors from drawing doses out of vials (FDA, updated 1 Oct 2026). Some people prefer a fixed-dose pen or tablet.
Rules for outsourcing facilities are tightening
On 30 April 2026 the FDA proposed keeping semaglutide off the 503B bulks list, finding no clinical need for outsourcing facilities to compound it (FDA news release). Comments closed on 29 June 2026.
Wanting a different molecule
Tirzepatide produced larger average weight loss in its own trials than semaglutide did in STEP 1, which leads some people to ask about Zepbound or compounded tirzepatide.
How we compared
For every option we state plainly whether it is FDA-approved. Evidence for approved drugs comes from their current FDA labels on DailyMed; for compounded products we say that no trial exists and cite the FDA's own statements. Prices come from NovoCare, Lilly, the makers' savings pages and Temi's product pages, all read on 5 October 2026. We did not test any product.
Prices checked on October 5, 2026
Alternatives
Wegovy pill (semaglutide 25 mg tablet)
- Kind
- FDA-approved GLP-1
- How it differs
- The same molecule as compounded semaglutide, made by Novo Nordisk and approved for weight management as a daily tablet. FDA-approved.
- Evidence
In OASIS 4 (Study 7 on the label), adults with obesity or overweight and no diabetes lost 13.6% of body weight on average over 64 weeks on the 25 mg tablet, compared with 2.4% on placebo; 76.3% lost at least 5% (Wegovy label). Each morning dose goes down with no more than 4 oz of plain water before food, and a 30-minute wait follows.
- Starting price
- $149 a month for the 1.5 mg starting tablet, $199 for 4 mg, $299 for 9 mg and 25 mg, self-pay (NovoCare Wegovy price page, checked 5 Oct 2026)
- Best for
- People who want FDA-approved semaglutide at a starting price close to compounded, without injections
- Tradeoffs
- The fasting routine is strict. The 25 mg maintenance dose costs about twice the starting dose. Thyroid C-cell boxed warning applies.
Wegovy pen (semaglutide injection)
- Kind
- FDA-approved GLP-1
- How it differs
- Brand semaglutide in a prefilled weekly pen with fixed doses up to 2.4 mg, or 7.2 mg as Wegovy HD. FDA-approved. No vial or syringe.
- Evidence
The Wegovy label reports STEP 1: average weight loss of 14.9% at 68 weeks on 2.4 mg versus 2.4% on placebo. The label also covers reducing major cardiovascular events in adults with heart disease and overweight. Any compounded vial borrows these numbers only by molecule; none was tested in STEP.
- Starting price
- New patients pay $199 twice at the lowest doses, then $349 through 2.4 mg; Wegovy HD costs $399 (NovoCare Wegovy price page, checked 5 Oct 2026)
- Best for
- People already used to weekly injections who want the approved product with trial evidence behind it
- Tradeoffs
- Costs more each month than most compounded vials. Same GI side effects. Switching from a vial means a new dosing plan from your prescriber.
Ozempic pen or pill (semaglutide)
- Kind
- FDA-approved GLP-1
- How it differs
- Novo Nordisk's semaglutide for type 2 diabetes, as a weekly pen or a daily tablet. FDA-approved, but not for weight management.
- Evidence
In the Ozempic pen's 30-week monotherapy trial, HbA1c fell 1.6 points on 1 mg against 0.1 on placebo (Ozempic label). The tablet shares a label with Rybelsus and is labeled to lower major cardiovascular events in high-risk adults with diabetes. Neither label includes a weight-loss indication.
- Starting price
- Pill $149 (1.5 mg) to $299 (9 mg) a month; pen $199 for two introductory fills, then $349 up to 1 mg or $499 at 2 mg (NovoCare Pharmacy, checked 5 Oct 2026)
- Best for
- Adults with type 2 diabetes who were using compounded semaglutide and want the approved diabetes product
- Tradeoffs
- Used for weight alone, it is off-label and coverage is unlikely. Pill strengths do not match Wegovy's.
Zepbound (tirzepatide)
- Kind
- FDA-approved GLP-1
- How it differs
- Eli Lilly's weekly GIP and GLP-1 dual agonist for weight management and obstructive sleep apnea with obesity. FDA-approved; vials sold for cash.
- Evidence
SURMOUNT-1 reported average weight loss at 72 weeks of 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo, in adults without diabetes (Zepbound label). No trial compares it with compounded semaglutide. Trial averages; individual results vary.
- Starting price
- From $299 a month (2.5 mg); 5 mg is $399, and 7.5 to 15 mg are $449 when you refill on time (Zepbound savings page, checked 5 Oct 2026)
- Best for
- People who want the approved drug with the largest average weight loss on its label
- Tradeoffs
- More expensive than compounded semaglutide at every dose. The cheapest format is a vial drawn up with a syringe. Same thyroid boxed warning.
Foundayo (orforglipron)
- Kind
- FDA-approved GLP-1
- How it differs
- A daily small-molecule GLP-1 tablet from Lilly for weight management, approved April 2026. FDA-approved; no food or water restrictions.
- Evidence
ATTAIN-1 (Trial 1 on the label) found average weight loss at 72 weeks of 7.4% on 5.5 mg, 8.3% on 9 mg and 11.1% on 17.2 mg, compared with 2.1% on placebo, in adults without diabetes (Foundayo label). Those averages are below semaglutide 2.4 mg's in STEP 1, though the trials differ.
- Starting price
- $149 per month at 0.8 mg; through 2026, 2.5 mg is also $149 and 5.5 mg $199; 9 mg is $299 (Foundayo savings page, checked 5 Oct 2026)
- Best for
- People who want an approved pill with an entry price near compounded and no fasting routine
- Tradeoffs
- Smaller average loss than injectable semaglutide. New, so less real-world data. Higher doses cost $299 or more.
Compounded tirzepatide injection
- Kind
- compounded (not FDA-approved)
- How it differs
- Tirzepatide made by a 503A compounding pharmacy in a multi-dose vial, often with an added ingredient. Not Zepbound or Mounjaro, and not FDA-approved.
- Evidence
No compounded tirzepatide product has been through a clinical trial, so SURMOUNT figures belong to Zepbound only. The FDA had received more than 730 adverse event reports for compounded tirzepatide by 31 May 2026 and warns about dosing errors with multi-dose vials (FDA, updated 1 Oct 2026). The tirzepatide shortage was declared resolved in December 2024.
- Starting price
- An 8.5 mg vial is $104.99 in California, or $143.99 with Temi's $39 order fee (Temi compounded tirzepatide page, checked 5 Oct 2026)
- Best for
- Cash payers who want a different molecule and accept a non-FDA-approved preparation after discussing it with a clinician
- Tradeoffs
- Swaps one unapproved product for another. Costs more per month than compounded semaglutide. Dosing in units from a vial adds room for error.
Compounded semaglutide pill or ODT
- Kind
- compounded (not FDA-approved)
- How it differs
- Semaglutide compounded into a daily tablet or orally dissolving tablet, sometimes with pyridoxine or naltrexone. Not FDA-approved and not the Wegovy pill.
- Evidence
There is no published trial of any compounded semaglutide tablet. The approved tablets need an absorption enhancer and fasting rules because so little semaglutide is absorbed: about 0.4% to 1% (Rybelsus and Ozempic tablets label). Whether a compounded tablet delivers a comparable dose is unknown. Temi describes these as separate, non-FDA-approved preparations.
- Starting price
- From $85 per 30-count pack (60 mg total) in California, plus the $39 service fee per order (Temi compounded semaglutide pill page, checked 5 Oct 2026)
- Best for
- People who want to stop injecting, have discussed the evidence gap, and prefer to stay on compounded semaglutide
- Tradeoffs
- Least evidence of any option here. 28-day beyond-use date, so packs cannot be stockpiled. Not FDA-approved.
Contrave (naltrexone and bupropion ER)
- Kind
- FDA-approved other weight-loss drug
- How it differs
- Not a GLP-1. A twice-daily tablet combining an opioid antagonist with an antidepressant, approved for chronic weight management. FDA-approved, not controlled.
- Evidence
Across 56 weeks in COR-BMOD, where everyone also had intensive behavioral counseling, average weight change was -8.1% on Contrave against -4.9% on placebo; in COR-I without that program it was -5.4% against -1.3% (Contrave label). It has a boxed warning on suicidal thoughts and behaviors.
- Starting price
- $99 a month with free shipping through the CurAccess Patient Support Program (Contrave.com, checked 5 Oct 2026)
- Best for
- People who cannot or do not want to take a GLP-1, including those with a personal or family history of MTC
- Tradeoffs
- Smaller average loss than semaglutide. Can raise blood pressure and heart rate; not for seizure disorders or with opioid use.
Qsymia (phentermine and topiramate ER)
- Kind
- FDA-approved other weight-loss drug
- How it differs
- Not a GLP-1. A once-daily capsule pairing an appetite suppressant with topiramate. FDA-approved for chronic weight management; Schedule IV controlled.
- Evidence
In Study 2 on the label, adults with overweight or obesity and related conditions lost 9.8% of body weight on 15 mg/92 mg and 7.8% on 7.5 mg/46 mg at week 56, against 1.2% on placebo (Qsymia label). Topiramate can harm a developing baby, so Qsymia is dispensed under a REMS program.
- Starting price
- $75 for a 30-day prescription with the manufacturer discount; $65.99 for Costco members (Qsymia.com, checked 5 Oct 2026)
- Best for
- Adults who want an approved oral non-GLP-1 option at a low fixed monthly price
- Tradeoffs
- Controlled substance, so Temi cannot prescribe it. Raises heart rate; tingling, dry mouth and insomnia are common.
Which to choose
| If you | Consider | Why |
|---|---|---|
| Want the same molecule with FDA approval and no needles | Wegovy pill | It is approved semaglutide for weight, starting at $149 a month. Ask your prescriber how your compounded dose relates to the tablet doses. |
| Prefer to keep a weekly injection | Wegovy pen | Fixed doses in a pen remove the unit-conversion step that the FDA links to compounded dosing errors. |
| Have type 2 diabetes | Ozempic pen or pill | These are the semaglutide products labeled for blood sugar and cardiovascular risk, which is also the route insurers recognize for diabetes. |
| Want the largest average loss on an approved label | Zepbound | SURMOUNT-1 averages reached 20.9% at 15 mg. Ask whether the higher cash price fits your budget long term. |
| Need the lowest monthly cost and accept no FDA approval | Staying on compounded semaglutide or the compounded pill | Compounded options remain the cheapest semaglutide route, but quality depends on the pharmacy and no trial supports them. |
| Cannot take any GLP-1 | Contrave or Qsymia | Neither carries the thyroid C-cell boxed warning. Each has its own warnings to go through with your prescriber. |
Switching
Compounded vials are dosed in units of a concentration chosen by the pharmacy, so the number on your syringe does not translate straight into a pen or tablet strength. That is a prescriber's calculation, and many people restart lower and step up again. Before the visit, write down your vial's concentration in mg/mL, the units you inject and the date of your last dose, then ask: which starting dose of the new medicine fits where I am now? Changing provider at the same time? Read switching GLP-1 providers with no break in treatment.
Frequently asked questions
What is the closest FDA-approved alternative to compounded semaglutide?
Wegovy, because it is the same molecule approved for weight management. You can take it as a once-weekly injection, including the 7.2 mg Wegovy HD dose, or as a daily 25 mg tablet. For type 2 diabetes, Ozempic is the approved semaglutide. Self-pay prices start at $149 a month for the Wegovy pill (NovoCare Wegovy price page, checked 5 Oct 2026).
Is compounded semaglutide still legal in 2026?
In limited circumstances. The FDA says a compounded drug may be appropriate when a patient's medical need cannot be met by an FDA-approved drug, and that a 503A pharmacy may not regularly make essentially copies of an approved product unless a prescriber documents a significant difference for that patient. Semaglutide is not on the FDA shortage list (FDA compounding policy page, 1 Apr 2026 update).
What is the cheapest FDA-approved alternative to compounded semaglutide?
Among GLP-1 drugs, the lowest self-pay dose of the Wegovy pill and of Foundayo each costs $149 a month (NovoCare and Foundayo savings page, checked 5 Oct 2026). Outside the class, Qsymia costs $75 for 30 days with the maker's discount. Compare the maintenance dose price too, since both GLP-1 tablets cost more at higher strengths.
Are semaglutide drops, sprays or 'research peptides' a safe alternative?
None of them is FDA-approved. The FDA has warned companies selling semaglutide labeled "for research purposes" or "not for human consumption" to consumers with dosing instructions, and says such products are of unknown quality. It advises buying only from state-licensed pharmacies with a prescription (FDA, updated 1 Oct 2026).
Can I switch from compounded semaglutide to Wegovy?
Yes, with a new prescription, but the dose does not carry over automatically. Compounded vials vary in concentration and sometimes contain added ingredients, while Wegovy has fixed label doses and its own escalation schedule. Give your prescriber the vial strength, your units per dose and when you last injected, and let them choose the starting dose.
Does Temi offer FDA-approved alternatives to compounded semaglutide?
Partly. A Temi physician can prescribe Foundayo and Zepbound when clinically appropriate, and LillyDirect dispenses them, not Temi. Temi itself sells compounded semaglutide and tirzepatide, which it describes as separate, non-FDA-approved preparations, with a $39 prescription service per order (usetemi.com/how-it-works, checked 5 Oct 2026).
Sources
- FDA's concerns with unapproved GLP-1 drugs used for weight loss (US Food and Drug Administration, updated 1 Oct 2026) (checked October 5, 2026)
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (shortage resolutions and 503A/503B timelines) (checked October 5, 2026)
- FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (FDA news release, 30 Apr 2026) (checked October 5, 2026)
- Compounded semaglutide injection, prices by pharmacy (Temi) (checked October 5, 2026)
- Compounded tirzepatide injection, prices by pharmacy (Temi) (checked October 5, 2026)
- Compounded semaglutide pill, prices by pharmacy (Temi) (checked October 5, 2026)
- How Temi works, including the $39 prescription service fee (Temi) (checked October 5, 2026)
- Wegovy (semaglutide) injection and tablets prescribing information, DailyMed (checked October 5, 2026)
- Wegovy pill and pen self-pay prices, NovoCare (Novo Nordisk) (checked October 5, 2026)
- Ozempic (semaglutide) injection prescribing information, DailyMed (checked October 5, 2026)
- Rybelsus and Ozempic tablets (semaglutide) prescribing information, DailyMed (revised 1/2026) (checked October 5, 2026)
- Ozempic pill and pen self-pay prices, NovoCare Pharmacy (Novo Nordisk) (checked October 5, 2026)
- Zepbound (tirzepatide) prescribing information, DailyMed (checked October 5, 2026)
- Zepbound coverage and savings, including LillyDirect self-pay prices (Eli Lilly) (checked October 5, 2026)
- Foundayo (orforglipron) prescribing information, DailyMed (checked October 5, 2026)
- Foundayo coverage and savings, including self-pay prices (Eli Lilly) (checked October 5, 2026)
- Contrave (naltrexone and bupropion extended-release) prescribing information, DailyMed (checked October 5, 2026)
- Contrave cost and savings, CurAccess program (Currax) (checked October 5, 2026)
- Qsymia (phentermine and topiramate extended-release) prescribing information, DailyMed (checked October 5, 2026)
- Qsymia cost and savings options (Vivus) (checked October 5, 2026)
Compounded semaglutide and compounded tirzepatide are not FDA-approved generics of the brand-name products. A licensed 503A compounding pharmacy prepares each one for a single prescription.
Get started
Start online, and a licensed physician reviews your request
A short online questionnaire is the first step. No appointments and no insurance needed.
A licensed physician reviews every request. Nothing on this page is a prescription.